The researchers, led by Dr Arthur Yee, believe that tumor necrosis factor- alpha) may have an important role in the clinical exacerbation of sarcoidosis.
Infliximab, an anti-human TNF-alpha monoclonal antibody, was used to treat a 72-year-old woman with complicated sarcoidosis.
|Tumor necrosis factor-alpha may be an important mediator of disease in sarcoidosis.
|Annals of Internal Medicine|
The patient presented with severe protein-losing enteropathy, hypoalbuminemia, and proximal myopathy.
Previous corticosteroid treatment was unsuccessful.
The patient was given an intravenous infusion of infliximab, 5 mg/kg body weight. Infusions were repeated at 2 and 6 weeks.
The results of the case report, published in the 3 July edition of the Annals of Internal Medicine, show that infliximab therapy resolved enteropathic and myopathic symptoms. It also improved serum albumin levels.
The therapy was discontinued when the patient developed a hypercoagulable state, associated with circulating anticardiolipin antibodies.
Dr Yee concludes, "Infliximab therapy was successful, but may cause adverse effects associated with cytokine cascade manipulation".